SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of “Hold” by Analysts

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) has been assigned a consensus rating of “Hold” from the eight research firms that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $52.57.

A number of equities research analysts have recently issued reports on SWTX shares. Guggenheim reissued a “neutral” rating and issued a $47.00 price target on shares of SpringWorks Therapeutics in a report on Monday, May 12th. TD Cowen reissued a “hold” rating and issued a $47.00 price target (down from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Barclays reissued an “equal weight” rating and issued a $47.00 price target (down from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Wedbush reaffirmed a “neutral” rating and issued a $47.00 target price (down from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $47.00 target price (down from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th.

SpringWorks Therapeutics Trading Up 0.2%

Shares of SpringWorks Therapeutics stock opened at $46.87 on Tuesday. SpringWorks Therapeutics has a 12-month low of $28.21 and a 12-month high of $62.00. The company has a market cap of $3.53 billion, a price-to-earnings ratio of -13.47 and a beta of 0.70. The company’s 50-day moving average price is $44.28 and its 200-day moving average price is $43.87.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The firm had revenue of $49.09 million during the quarter, compared to analysts’ expectations of $64.19 million. On average, sell-side analysts predict that SpringWorks Therapeutics will post -2.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Huntington National Bank lifted its position in SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after buying an additional 192 shares during the period. AlphaQuest LLC grew its stake in shares of SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after acquiring an additional 414 shares during the period. Twin Tree Management LP bought a new position in shares of SpringWorks Therapeutics during the 1st quarter valued at approximately $37,000. Venturi Wealth Management LLC purchased a new position in SpringWorks Therapeutics in the 4th quarter worth approximately $45,000. Finally, State of Wyoming raised its holdings in shares of SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock worth $55,000 after acquiring an additional 433 shares in the last quarter.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.